Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03769766 · ClinicalTrials.gov registry record · Phase 3
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
A Phase 3 study of Prostate Cancer, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
- 1
- Study location
NCT03769766 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 291 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03769766, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Curcumin
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2030-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03769766
The ClinicalTrials.gov registry entry for NCT03769766 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (52% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03769766 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03769766 about?
NCT03769766 is a clinical study titled "Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance". This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
What is the current status of trial NCT03769766?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2019-03-11. Estimated completion is 2030-11.
What conditions does trial NCT03769766 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03769766?
The interventions under investigation include: Placebo (DRUG), Curcumin (DRUG).
Who is sponsoring clinical trial NCT03769766?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03769766 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.